Form 8-K - Current report:
SEC Accession No. 0001213900-24-091170
Filing Date
2024-10-28
Accepted
2024-10-28 16:00:18
Documents
14
Period of Report
2024-10-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0218711-8k_inmune.htm   iXBRL 8-K 23854
2 PRESS RELEASE DATED OCTOBER 28, 2024 ea021871102ex99-1_inmune.htm EX-99.1 15271
  Complete submission text file 0001213900-24-091170.txt   219445

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20241028.xsd EX-101.SCH 3018
4 XBRL LABEL FILE inmb-20241028_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE inmb-20241028_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0218711-8k_inmune_htm.xml XML 3793
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 241400815
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)